Related Experiment Video
Updated: Jan 25, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Efficacy and Safety of Imatinib in Paediatric CML - A Single Centre Study
Cynthia Smeding1, Aleksandra Szydło1, Krzysztof Pieluszczak1
1Student Scientific Group 'SPHEROCYTE', Department of Paediatric Haematology and Oncology, Medical University of Warsaw, Warsaw, Poland.
Background/Aim:
Chronic myeloid leukaemia (CML) rarely affects the paediatric population and has an incidence of 0.06-0.12/100,000 children per year. The dire clinical course of paediatric CML is further exacerbated by the adverse effects of long-term imatinib therapy.
Patients And Methods:
Our cohort comprised 14 CML patients who were treated with imatinib between July 2010 and September 2018. The European Leukaemia Net (ELN) standard milestones of response criteria were used to evaluate its therapeutic effectiveness.
Results:
Complete haematological remission and partial cytogenetic response were achieved in all patients. Complete cytogenetic response was achieved in seven patients. Major molecular response was achieved in six patients. Two patients underwent haematopoietic stem cell transplantation due to unsatisfactory response to imatinib.
Conclusion:
Imatinib is effective in treating paediatric CML and limits the progression to advanced stages, however, the quality of life still needs to be optimised.
Related Concept Videos
Survey Safety
Self-Efficacy
Household Wiring And Electrical Safety
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dose-Response Relationship: Potency and Efficacy
Case Studies

